Clinical Trial Update: Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Relapsed Multiple Myeloma, End-stage Renal Disease | Phase 1 | Status: COMPLETED | Results posted: 2016-05-04